• Bing-bing Pei, Chao-yue Li, Xin Lu, Xing Wu, Liang Gao, Jian Yu, Xue-hai Wu, Yi Jin, Yi-rui Sun, Zhuo-ying Du, Ying Mao, Jin Hu, and Liang-fu Zhou.
• Department of Neurosurgery, Affiliated Huashan Hospital, Fudan University, Shanghai 200040, China.
• Zhonghua Yi Xue Za Zhi. 2013 Jun 18;93(23):1780-3.

ObjectiveTo explore the role of small-dose recombinant human coagulation factor VIIa (rFVIIa) for coagulopathy in patients with isolated traumatic brain injury.MethodsA total of 86 isolated traumatic brain patients with coagulopathy were treated at our neurosurgery intensive care unit (NICU) from January 2010 to December 2012. Their trauma registry data included mortality, pre-and post-rFVIIa coagulation parameters. Two-tailed paired t-test was used to determine significant changes in coagulation parameters and other major clinical parameters.ResultsTwenty-seven patients made up the low-dose rFVIIa (20 µg/kg) group. And the control group had 59 well-matched subjects. At admission, age, blood pressure, Glasgow coma scale score, hemoglobin, platelets and international normalize ratio were similar in both groups. After treatment, the INR of patients on rFVIIa was lower than that of the conventional treatment group (1.1 ± 0.2 vs 1.2 ± 0.2, P < 0.01) and it declined more in the rFVIIa group (0.3 ± 0.2 vs 0.1 ± 0.4, P = 0.05). No significant difference existed in mortality or length of stay between two groups.There was no occurrence of subsequent thromboembolic events.ConclusionThe application of small-dose rFVIIa can effectively reduce the value of INR and improve the coagulation status of patients. During the course of treatment, no major adverse events occur.

17 keywords...

hide…